Research
Hormonal
Gut microbiota alterations in obesity contribute to chronic low-grade inflammation through increased lipopolysaccharide (LPS) translocation, which triggers immune responses and insulin resistance.
High levels of bacterial toxins (LPS) can leak into your bloodstream if your gut barrier is compromised, causing inflammation and insulin resistance. A diet rich in fiber and fermented foods may support gut barrier integrity.
ModerateSupportsMEDIUM confidence
Chronic low-grade inflammation is generally regarded as one of the fundamental characteristics of obesity, which is mainly triggered by LPS... The increment of LPS can destruct the gut barrier... resulting in elevated LPS levels in circulation... LPS... contributes to the secretion of proinflammatory cytokines and chemokines
Why this rating
Review paper citing multiple studies.
Source
The critical role of gut microbiota in obesity
Zilu Cheng et al. · Frontiers in Endocrinology · 2022
DOI 10.3389/fendo.2022.1025706
narrative_reviewCited 222×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Obesity is associated with gut dysbiosis characterized by decreased microbial diversity and an increased Firmicutes/Bacteroidetes ratio, which contributes to obesity through disrupted energy homeostasis, lipid synthesis, and chronic inflammation.Moderate
- Altered gut microbiota in obesity increases digestible energy uptake from food through enhanced expression of nutrient transporters and fermentation enzymes, leading to increased caloric absorption.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →